THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
Inventor
Julien, Jean-Philippe
Rujas Diez, Edurne
Treanor, Bebhinn
Zhao, Tian Tian
Abstract
In aspects, a self-assembled polypeptide complex comprises (a) a plurality of first fusion polypeptides, each first fusion polypeptide comprising (1) an Fc polypeptide linked to (2) a nanocage monomer or subunit thereof, wherein the Fc polypeptide comprises a Fc chain having one or more mutations relative to a reference Fc chain of the same Ig class, and (b) a plurality of second fusion polypeptides, each second fusion polypeptide comprising (1) an antigen-binding antibody fragment linked to (2) a nanocage monomer or subunit thereof.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided herein is a fusion protein comprises a nanocage monomer linked to a SARS-CoV-2 binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also provided is a tri-specific antibody construct targeting SARS-CoV-2. Also provided is a fusion polypeptide comprising (1) a fragment crystallizable (Fc) region linked to (2) a nanocage monomer or subunit thereof, wherein the Fc region comprises the I253A mutation, wherein numbering is according to the EU index.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
MAX-PLANCK-GESSELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E V. (Germany)
Inventor
Wardemann, Hedda
Murugan, Rajagopal
Obraztsova, Anna
Levashina, Elena
Costa, Giulia
Julien, Jean-Philippe
Prieto, Katherine
Thai, Elaine
Abstract
Described herein is malarial immnunogen or a variant thereof comprising at least a portion of the wild-type PfCSP amino acid sequence lacking a KQ motif. In aspects, the malarial immunogen is lacking a KQP motif. For example, the immnunogens described herein, in aspects, exclude the C-terminal domain of PfCSP. In other aspects, the immunogens described herein specifically exclude a KQ or KQP motif. In aspects the immunogens described herein exclude an N-terminal KQ or KQP motif, which is part of the N-terminal junction region in PfCSP.
A method of diagnosing congenital heart block or risk of congenital heart block in a fetal or infant subject is provided. The method includes the step of detecting in a biological sample obtained from the mother of the subject one or more maternal autoantibodies which bind to target cardiomyocyte proteins of the subject. A kit for use in to detect such maternal autoantibodies is also provided.
The present disclosure provides anti-commensal antibody (ACAb)-based profiles and methods of selecting a subject at risk of developing type 1 diabetes (T1D) for treatment with an anti-CD3 antibody. Also provided is a method of treating a subject at risk of developing T1D with an anti-CD3 antibody when the subject has an ACAb-based profile that predicts the subject is a responder the treatment. Further provided are ACAb-based profiles and methods of predicting that a subject at risk of developing T1D will progress to T1D.
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
6.
NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
The Governing Council of the University of Toronto (Canada)
Inventor
Julien, Jean-Philippe
Sicard, Taylor
Semesi, Anthony
Treanor, Bebhinn
Zhao, Tiantian
Diez, Edurne Rujas
Abstract
A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
7.
HIV-1-TARGETED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
In aspects, fusion polypeptides comprising an HIV-1 binding moiety and a nanocage monomer (e.g., ferritin) or subunit thereof are described herein. In aspects, self-assembled polypeptide complexes comprising such fusion polypeptides are also described, including multispecific self-assembled polypeptide complexes whose HIV-1 binding moieties collectively target more than one epitope on HIV-1.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
16 - Paper, cardboard and goods made from these materials
18 - Leather and imitations of leather
25 - Clothing; footwear; headgear
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Advertising flyers; booklets; bulletins; calendars; catalogues; colouring sets; cook books; correspondence cards; day planners; decals; desk diaries; document covers; document portfolios; drawing pads; educational books; erasers; gift cards; gift-wrapping paper; greeting cards; iron-on transfers; lanyards for holding visiting cards; leaflets; medical identification cards; medical publications; memo pads; newsletters; note books; note cards; note holders; pamphlets; pen and pencil cases; pencils; pens; periodical publications; planners for stationery use; posters; printed tickets for charitable events; self-stick notes; thank you cards; writing instruments; yearly planners
(2) All purpose sport bags; all-purpose carrying bags; backpacks; beach bags; book bags; bum bags; carry-all bags; carrying cases for documents; cases for keys; children's shoulder bags; daypacks; drawstring bags; duffel bags; fanny packs; grocery tote bags; gym bags; messenger bags; reusable shopping bags; rucksacks; school bags
(3) Athletic apparel; athletic wear; baby clothing; bandanas; baseball caps; bath wraps; blanket sleepers; booties; caps; casual clothing; children's clothing; children's footwear; children's shirts; cloth bibs; cloth hats; fleece jackets; fleece pullovers; flip-flops; gloves; golf caps; golf hats; golf shirts; hats; head bands; head scarves; head sweatbands; headscarves; hooded sweatshirts; hooded tops; infant clothing; infant footwear; jackets; jump suits; kerchiefs; lab coats; long sleeve pullovers; long-sleeved t-shirts; loungewear; maternity wear; mittens; neck ties; neck warmers; neckerchiefs; nightwear; novelty hats; pajamas; promotional caps; promotional t-shirts; pullovers; rain boots; rain hats; rain ponchos; rainwear; shawls; shorts; shoulder scarves; shower caps; slipper socks; slippers; smocks; socks; softball caps; sports caps and hats; sports clothing; sun hats; sun protective clothing; sweat bands; sweat pants; sweat shirts; sweat socks; swim caps; swim suits; t-shirts; tank tops; toques; wrist bands (1) Advertising planning services; advertising services for promoting public awareness of the benefits of general health and wellness; advertising services for promoting public awareness of the benefits of healthy food; advertising services for promoting public awareness of the benefits of nutrition; advertising services for promoting public awareness of the benefits of nutritious cooking; advertising services for promoting public awareness of the benefits of physical activity; advertising services for promoting public awareness of the need for organ and tissue donation; advertising services to promote public awareness of medical conditions; advertising services to promote public awareness on educational issues; advertising services to promote public awareness on healthcare issues; advertising services to promote public awareness on public policy issues; advertising services to promote the charitable works of others; advertising the goods and services of others through all public communication means; advertising the goods and services of others via social media; advertising, promotion and marketing services in the nature of e-mail blast campaigns for others; arranging, organizing and conducting exhibitions for promoting public awareness of the mental health and wellness; association services for promoting the public interest and awareness in cancer research and education; charitable services in the nature of organizing and conducting volunteer programs; compilation, production and dissemination of advertising matter for others; creation of advertising content for third parties for display on digital signage and management of such advertising content; developing and managing the charitable giving programs of others; distribution of advertising materials for others; online sale of lottery tickets; organizing and conducting charity auctions for charitable fundraising purposes; public advocacy to promote access to quality healthcare for children; retail sale of lottery tickets
(2) Acceptance of monetary charitable contributions; acceptance of monetary charitable contributions to fund medical research; accepting monetary charitable contributions to fund medical research; arranging charitable fundraising activities; charitable foundation services, namely, providing financial assistance for programs and services of others; charitable fund raising; financial sponsorship of medical research; financing of medical research; providing information relating to charitable fund raising; services of operating a foundation for the purpose of raising and disseminating funds to promote access to quality healthcare for children
(3) Services of operating a foundation for the purpose of raising and disseminating funds to educate in respect of paediatric disorders and diseases and to further research in the fields of preventing and treating paediatric disorders and diseases;
(4) Arranging and conducting community events and fundraisers for users of paediatric healthcare services, their families and supporters, for entertainment and educational purposes; arranging and conducting community social charitable fundraising events; event planning; lottery services; online publication of electronic books and periodicals; organisation of conferences and symposia in the field of medical science; organization of music concerts for charitable purposes; publication of electronic books and periodicals online; publishing of journals, books and handbooks in the field of medicine
(5) Providing information about medical research; providing medical research information in the field of clinical trials
9.
MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2
A self-assembled polypeptide complex comprises: (a) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to an Fc polypeptide, and (b) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to a SARS-COV-2 binding moiety; wherein a plurality of the fusion proteins self-assemble to form a nanocage.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
10.
RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT
Herein in provided a recombinant polypeptide comprising a polypeptide for preventing or reducing interaction between the human proteins EAG2 and KvB2, and a cell-penetrating peptide. The polypeptide may comprise a portion of Kvß2 from or encompassing a region that is important for the interaction between the two proteins, such as, e.g., a contiguous portion of human Kvß2 (SEQ ID NO: 26) encompassing at least amino acids 90 to 114 thereof. Retro-inverso polypeptides based on such recombinant polypeptides are also described. The EAG2-Kvß2 complex is herein identified as a therapeutic target for certain cancers. Herein are also disclosed therapeutic applications of the recombinant polypeptide in treatment of such cancers, including gliomas, such as low-grade gliomas or glioblastomas, which may be recurrent and/or resistant to conventional treatment.
Self-assembled polypeptide complexes comprising 1) fusion polypeptides comprising Fc polypeptides linked to nanocage monomers or subunits thereof and 2) fusion polypeptides comprising an antigen-binding antibody fragment capable of binding to DR5.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
12.
OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
13.
SYSTEM AND METHOD FOR CANCER-CELL SPECIFIC TRANSCRIPTION IDENTIFICATION
The present invention relates a system and method for cancer-cell specific transcription identification. The method including: receiving nucleic acid data from one or more samples; determining variant allele fraction (VAF) of markers in ribonucleic acid (RNA) in the nucleic acid data and markers for deoxyribonucleic acid (DNA) in the nucleic acid data; comparing the VAF of the RNA relative to the DNA for each of the markers; and outputting the comparison as a quantification of cancer-cell specific changes in transcriptional output as a marker of prognosis or therapeutic response in cancer.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
14.
MOLECULES THAT BIND TO PROTOGENIN (PRTG) POLYPEPTIDES
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
The Hospital for Sick Children (Canada)
Inventor
Dimitrov, Dimiter Stanchev
Chen, Chuan
Li, Wei
Sun, Zehua
Taylor, Michael D.
Visvanathan, Abhirami
Saulnier, Olivier
Abstract
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a PRTG polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a PRTG polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
15.
APPLICATIONS OF POLYPEPTIDES INHIBITOR OF EAG2 - KVß2 INTERACTION IN CANCER IMMUNOTHERAPY
Described herein are immunostimulatory effects of an anti-tumor polypeptide that targets the interaction between EAG2 and Kvß2, allowing for applications in cancer immunotherapy. Described is a combination therapy for cancer comprising a recombinant polypeptide comprising a polypeptide for preventing or reducing interaction between EAG2 and Kvß2 comprising i) at least 5 contiguous amino acids from a region of human Kvß2 selected from the group consisting of amino acids 1 to 67 thereof, amino acids 90 to 114 thereof, and amino acids 343 to 355 thereof, or ii) a polypeptide that is at least 70% identical to i); and a cell-penetrating peptide, or a retro-inverso version of said polypeptide; and an agent for cancer immunotherapy. The polypeptide may comprise SEQ ID NO: 1. The cancer may be glioblastoma. Pharmaceutical compositions, uses, and methods are also described, along with gene expression signatures predictive of improved responsiveness.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
16.
ALVEOLAR BONE GRAFT (ABG) SIMULATOR AND METHOD OF USE THEREOF
A simulator for practicing alveolar bone graft (ABG) surgery, comprising: a cartridge configured to incorporate an oral cavity having a cleft of the alveolus formed therein; a model that resembles a human face wherein to which cartridge can removably attached, and a base configured to removably attach to the model. Such simulator being configured specifically to reflect the physical elements of an oral cleft that can be corrected by an ABG and comprising elements that are formed from materials that are similar in characteristics to the corresponding elements of such a human cleft. Elements are formed individually and connected in manner that forms: layers of elements; and positioning of and interactions between elements to assist with training of ABG surgical skills. Surgical procedures for ABG may be performed upon the simulator utilizing the same surgical tools and steps, and having the same feel, as performing surgery upon a human subject.
In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage comprising one or more Fc dimers. In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer or scFc fragment at the C-terminus of the nanocage monomer or subunit thereof, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
18.
METHOD FOR DIAGNOSIS OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
A method of detecting a DSG2 autoantibody in a mammal is provided. The method includes contacting a biological sample obtained from a mammal with DSG2; and detecting the presence of DSG2 autoantibody bound to the DSG2 with a detectable anti-human antibody by detecting binding of the anti-human antibody to the DSG2 autoantibody. The method is useful to diagnose ARVC in a mammal.
A method and kit for predicting preeclampsia is provided. Levels of Jumonji C domain containing protein 6 (JMJD6) and fibronectin are measured in placenta-derived small extracellular vesicles isolated from a subject. The levels of JMJD6 and fibronectin are compared to a non-preeclamptic control. If levels of JMJD6 are depressed and levels of fibronectin are elevated, the subject may be monitored or treated for preeclampsia.
Described herein are examples of instrument assemblies for navigating a craniofacial skeleton during craniosynostosis surgery. In some examples, the instrument assembly may comprise (a) a shaft extending between a proximal end and a distal end and at least a portion of the shaft may be articulable; (b) a drive unit operatively coupled to the articulable section of the shaft for controlling movement of the articulable section; and (c) an interchangeable tool having an end-effector and an end-effector control system for controlling actuation of the end-effector. The interchangeable tool may be operatively coupled to the shaft. When in use, the articulable section may be configured to provide at least one degree of freedom of motion to the end-effector.
Non-signaling mutant signal regulatory protein alpha (SIRPα) is provided, including a transgene encoding the SIRPα mutant and cells expressing the SIRPα mutant. Non-signaling mutant SIRPα is modified such that the signaling that results in inhibition of phagocytosis when SIRPα binds to its CD47 ligand is blocked or disrupted, thereby enabling phagocytosis to occur. This renders the cells expressing the mutant useful as a decoy sink for CD47-expressing cells such as cancer cells. Therapeutic methods of using cells expressing the SIRPα mutant are also provided.
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A fusion protein comprises a nanocage monomer or a subunit thereof linked to a DR4 and/or DR5 antigen-binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also described is a nanocage comprising the fusion protein and related compositions as well as methods and uses for treating and/or preventing cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
24.
TRACHEAL INTUBATION DEVICE FOR DELIVERY OF APNEIC OXYGENATION AND SUCTION
This disclosure discloses a tracheal intubation device designed to improve safety during intubation attempts. The device allows for the delivery of medical gas (such as oxygen) flow through the endotracheal tube itself during intubation attempts. This moves the source of apneic oxygen lower in the patient's airway to bypass anatomy that otherwise can obstruct medical gas flow. The device can also switch on-demand to generating suction through the endotracheal tube to clear away fluids that block the intubator's view and that block medical gas flow. There are currently no devices that can deliver both medical gas and on-demand suction using the endotracheal tube as the flow conduit during the process of intubation. The present device accomplishes these tasks while incorporating non-obvious elements to optimize its use and efficacy.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Julien, Jean-Philippe
Jetha, Arif
Muthuraman, Krithika
Ho, David D.
Abstract
Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus other than SARS-CoV-2. Also described are methods for treating and/or preventing sarbecovirus infection and/or a sarbecovirus-associated condition.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
Disclosed herein is a device that standardizes and automates pain testing in laboratory rodents by providing computer-controlled aiming and delivery of various somatosensory stimuli, and precisely measuring the evoked responses. For photostimuli, red light is incorporated into the light path and its reflectance off the paw is measured (at ≥1 kHz) by a photodetector mounted on the device. The reflectance signal changes rapidly when the target paw moves, thus enabling automated measurement of withdrawal latencies with millisecond precision. A camera mounted on the device, below the mouse, provides video for aiming and for behavior analysis before, during and after stimulation. The device can be aimed manually or automatically using artificial intelligence (AI), in the latter case, the target paw is identified and tracked by a pre-trained neural network, and real-time information about paw location is used to command motorized linear actuators to move the stimulator and to initiate stimulation.
Described herein is an anti-class II MHC antibody fused to a SARS-CoV-2 antigen. Also described is a vaccine comprising the antibody and methods for treating and/or preventing SARS-CoV-2, wherein the methods comprise administering the antibody to a subject in need thereof. In typical aspects, the vaccine is free of an adjuvant.
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
28.
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRPALPHA - CD47 INTERACTION
The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
29.
PYRIDAZINONE COMPOUNDS WHICH MODULATE MUTANT PROTEINS FOR TREATING RESPIRATORY DISEASES
The present disclosure relates to pyridazinone compound of the Formula (I) for the treatment of respiratory diseases, such as, chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, Long QT syndrome or Dravet syndrome, which arise as a result of mis-folded or mis-shaped proteins.
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
30.
IMMUNOGENIC PEPTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF MALARIA
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (Germany)
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (Germany)
Inventor
Julien, Jean-Philippe
Scally, Stephen
Prieto, Katherine
Wardemann, Hedda
Ludwig, Julia
Murugan, Rajagopal
Costa, Giulia
Levashina, Elena
Abstract
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: —KQPAa; QPAKa; PAKQa; or AKQPa; —NPDPb; PNPDb; DPNPb; or PNPDb; —NANPc; ANPNc; NPNAc; or PNANc; —NVDPd; VDPNd; DPNVd; or PNVDd; and —NANPe; ANPNe; NPNAe; or PNANe. wherein a, b, c, d, and e are each independently 0 or greater and wherein a±b±c±d±e is at least 2; and a nanocage monomer peptide.
Described herein in aspects is a humanized anti-class II MHC antibody, wherein the humanized antibody binds to class II MHC with similar or increased affinity and/or specificity as compared with a non-humanized anti-MHC class II antibody that specifically binds to a shared epitope on most or all HLA-DR molecules. Related methods and uses are also described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The disclosure features in some aspects methods for identifying subjects with constitutional mismatch repair deficiency (CMMRD), a mismatch repair deficiency (MMD) cancer, a polymerase proofreading deficiency (PPD) cancer, and/or a MMD&PPD cancer. The disclosure also features in some aspects methods for predicting response of a subject to immunotherapy.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
MAX-PLANCK-GESSELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E V. (Germany)
Inventor
Wardemann, Hedda
Murugan, Rajagopal
Obraztsova, Anna
Levashina, Elena
Costa, Giulia
Julien, Jean-Philippe
Prieto, Katherine
Thai, Elaine
Abstract
Described herein is malarial immunogen or a variant thereof comprising at least a portion of the wild-type PfCSP amino acid sequence lacking a KQ motif. In aspects, the malarial immunogen is lacking a KQP motif. For example, the immunogens described herein, in aspects, exclude the C-terminal domain of PfCSP. In other aspects, the immunogens described herein specifically exclude a KQ or KQP motif. In aspects the immunogens described herein exclude an N-terminal KQ or KQP motif, which is part of the N- terminal junction region in PfCSP.
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
18 - Leather and imitations of leather
25 - Clothing; footwear; headgear
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Audio books; decorative magnets; digital books downloadable from the Internet; downloadable digital books; downloadable digital content being videos; downloadable electronic books; downloadable electronic publications in the nature of information pamphlets; downloadable podcasts; downloadable posters; electronic agendas; electronic books; electronic medical publications; electronic periodicals; eyeglass lanyards; laptop carrying cases; mousepads; USB flash drives
(2) Advertising flyers; booklets; bulletins; calendars; catalogues; colouring sets; cook books; correspondence cards; day planners; decals; desk diaries; document covers; document portfolios; drawing pads; educational books; erasers; gift cards; gift-wrapping paper; greeting cards; iron-on transfers; lanyards for holding visiting cards; leaflets; medical identification cards; medical publications; memo pads; newsletters; note books; note cards; note holders; pamphlets; pen and pencil cases; pencils; pens; periodical publications; planners for stationery use; posters; printed tickets for charitable events; self-stick notes; thank you cards; writing instruments; yearly planners
(3) All purpose sport bags; all-purpose carrying bags; backpacks; beach bags; book bags; bum bags; carry-all bags; carrying cases for documents; cases for keys; children's shoulder bags; daypacks; drawstring bags; duffel bags; fanny packs; grocery tote bags; gym bags; messenger bags; reusable shopping bags; rucksacks; school bags
(4) Athletic apparel; athletic wear; baby clothing; bandanas; baseball caps; bath wraps; blanket sleepers; booties; caps; casual clothing; children's clothing; children's footwear; children's shirts; cloth bibs; cloth hats; fleece jackets; fleece pullovers; flip-flops; gloves; golf caps; golf hats; golf shirts; hats; head bands; head scarves; head sweatbands; headscarves; hooded sweatshirts; hooded tops; infant clothing; infant footwear; jackets; jump suits; kerchiefs; lab coats; long sleeve pullovers; long-sleeved t-shirts; loungewear; maternity wear; mittens; neck ties; neck warmers; neckerchiefs; nightwear; novelty hats; pajamas; promotional caps; promotional t-shirts; pullovers; rain boots; rain hats; rain ponchos; rainwear; shawls; shorts; shoulder scarves; shower caps; slipper socks; slippers; smocks; socks; softball caps; sports caps and hats; sports clothing; sun hats; sun protective clothing; sweat bands; sweat pants; sweat shirts; sweat socks; swim caps; swim suits; t-shirts; tank tops; toques; wrist bands (1) Advertising planning services; advertising services for promoting public awareness of the benefits of general health and wellness; advertising services for promoting public awareness of the benefits of healthy food; advertising services for promoting public awareness of the benefits of nutrition; advertising services for promoting public awareness of the benefits of nutritious cooking; advertising services for promoting public awareness of the benefits of physical activity; advertising services for promoting public awareness of the need for organ and tissue donation; advertising services to promote public awareness of medical conditions; advertising services to promote public awareness on educational issues; advertising services to promote public awareness on healthcare issues; advertising services to promote public awareness on public policy issues; advertising services to promote the charitable works of others; advertising the goods and services of others through all public communication means; advertising the goods and services of others via social media; advertising, promotion and marketing services in the nature of e-mail blast campaigns for others; arranging, organizing and conducting exhibitions for promoting public awareness of the mental health and wellness; association services for promoting the public interest and awareness in cancer research and education; charitable services in the nature of organizing and conducting volunteer programs; compilation, production and dissemination of advertising matter for others; creation of advertising content for third parties for display on digital signage and management of such advertising content; developing and managing the charitable giving programs of others; distribution of advertising materials for others; organizing and conducting charity auctions for charitable fundraising purposes
(2) Public advocacy to promote access to quality healthcare for children
(3) Acceptance of monetary charitable contributions; acceptance of monetary charitable contributions to fund medical research; accepting monetary charitable contributions to fund medical research; arranging charitable fundraising activities; charitable foundation services, namely, providing financial assistance for programs and services of others; charitable fund raising; financial sponsorship of medical research; financing of medical research; providing information relating to charitable fund raising; services of operating a foundation for the purpose of raising and disseminating funds to promote access to quality healthcare for children
(4) Services of operating a foundation for the purpose of raising and disseminating funds to educate in respect of paediatric disorders and diseases and to further research in the fields of preventing and treating paediatric disorders and diseases; services of operating a foundation for the purpose of raising and disseminating funds to promote access to quality healthcare for children
(5) Arranging and conducting community events and fundraisers for users of paediatric healthcare services, their families and supporters, for entertainment and educational purposes; event planning; lottery services; online publication of electronic books and periodicals; organisation of conferences and symposia in the field of medical science; organization of music concerts for charitable purposes; publication of electronic books and periodicals online; publishing of journals, books and handbooks in the field of medicine
(6) Arranging and conducting community events and fundraisers for users of paediatric healthcare services, their families and supporters, for entertainment and educational purposes; arranging and conducting community social charitable fundraising events
(7) Providing information about medical research; providing medical research information in the field of clinical trials
35.
System and method for cancer-cell specific transcription identification
The present invention relates a system and method for cancer-cell specific transcription identification. The method including: receiving nucleic acid data from one or more samples; determining variant allele fraction (VAF) of markers in ribonucleic acid (RNA) in the nucleic acid data and markers for deoxyribonucleic acid (DNA) in the nucleic acid data; comparing the VAF of the RNA relative to the DNA for each of the markers; and outputting the comparison as a quantification of cancer-cell specific changes in transcriptional output as a marker of prognosis or therapeutic response in cancer.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A method of diagnosing congenital heart block or risk of congenital heart block in a fetal or infant subject is provided. The method includes the step of detecting in a biological sample obtained from the mother of the subject one or more maternal autoantibodies which bind to target cardiomyocyte proteins of the subject. A kit for use in to detect such maternal autoantibodies is also provided.
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The present disclosure provides a resective epilepsy surgery simulator that incorporates biocompatible, dissectible materials as well as the surgical anatomy cues that would support the acquisition of the required technical skill set to ultimately broach the gap in surgical care for patients living with epilepsy. The simulator is produced by imaging a patient's brain and performing computer aided design to select the gray and white matter layers of the brain, the brain blood vessels, and the skull based on the imaging of the patient's brain and storing them in computer aided design files. These files are converted into a format readable by a 3D printer and programming the 3D printer to print the patient's brain simulator from the computer aided design files with the 3D printer containing multiple print-heads that extrude liquid polymer one multi-material layer at a time to produce a simulator of the patient's skull and brain.
A dynamic foot abduction bar for use with a pair of boots having a crossbar and a pair of generally L-shaped components. The generally L-shaped components are slidingly attached at either end of the crossbar, thereby allowing axial translation. The pair of boots are releasably attachable to the generally L-shaped components. The dynamic foot abduction bar may include a modified ball joint attached between the generally L-shaped component and the crossbar. The modified ball joint may be configured for upward coronal rotation, outward axial rotation and sagittal rotation.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
39.
SYSTEM AND METHOD FOR CLASSIFYING CANCER AND CLASSIFYING BENIGN AND MALIGNANT NEOPLASM
The present invention relates to systems and methods for classification of cancer from gene expression input data. The method including: receiving a training dataset including nucleic acid data points from one or more samples; identifying classes in the training dataset including performing recursive clustering by, at each successive iteration, performing a search to identify clusters based on similarity, wherein each class of the classes is associated with a tumor; training a machine learning model to associate the nucleic acid data points of the training dataset with the identified classes; receiving the gene expression input data for classification; classifying, using the trained machine learning model, the gene expression input data as one or more of the identified classes; and outputting the classification of the gene expression input data.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The Governing Council of the University of Toronto (Canada)
The Hospital for Sick Children (Canada)
Inventor
Diller, Eric
Shokrollahi, Peyman
Parkinson, John
Abstract
A magnetically actuated capsule comprising two portions pivotally connected to each other for allowing tetherless reconfiguration of the capsule between a closed configuration and an open configuration inside a body cavity by an external magnet. The capsule can be used for noninvasive sampling of microbiomes and liquid within a body cavity, or to release a cargo within the body cavity. Methods of using and manufacturing the capsule are disclosed.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
B29C 39/02 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor for making articles of definite length, i.e. discrete articles
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
41.
INHIBITORS OF CBL AUTOINHIBITION AND RELATED METHODS
Described herein are agents that inhibit CBL autoinhibition, agents that activate CBL, SLAP and/or SLAP2 mimetics, and recombinant SLAP and/or SLAP2 or variants and/or fragments thereof that inhibit CBL autoinhibition. Also described are fusion proteins comprising these molecules as well as methods of inhibiting CBL autoinhibition and related uses thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
42.
MOLECULES THAT BIND TO PROTOGENIN (PRTG) POLYPEPTIDES
UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
THE HOSPITAL FOR SICK CHILDREN (Canada)
Inventor
Dimitrov, Dimiter Stanchev
Chen, Chuan
Li, Wei
Sun, Zehua
Taylor, Michael D.
Visvanathan, Abhirami
Saulnier, Olivier
Abstract
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a PRTG polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a PRTG polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/385 - Haptens or antigens, bound to carriers
Generally, the present disclosure provides novel bacterial translocation domains for use in cellular delivery. An example is the translocation domain from the Austwickia chelonae protein of SEQ ID NO:2, the translocation domain having the amino acid sequence of SEQ ID NO: 3. Translocase domains from other bacterial strains and species are also described (e.g. SEQ ID NOs: 4 to 17 and 36 to 48). Recombinant polypeptides comprising these translocation domains are described. The recombinant polypeptides are intended for use in delivery of cargo molecules, including therapeutic polypeptides that may be used to treat disease.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)
C07K 14/36 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from ActinomycesPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptomyces (G)
C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
45.
RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT
Herein in provided a recombinant polypeptide comprising a polypeptide for preventing or reducing interaction between the human proteins EAG2 and Kvß2, and a cell-penetrating peptide. The polypeptide may comprise a portion of Kvß2 from or encompassing a region that is important for the interaction between the two proteins, such as, e.g., a contiguous portion of human Kvß2 (SEQ ID NO: 26) encompassing at least amino acids 90 to 114 thereof. Retro-inverso polypeptides based on such recombinant polypeptides are also described. The EAG2-Kvß2 complex is herein identified as a therapeutic target for certain cancers. Herein are also disclosed therapeutic applications of the recombinant polypeptide in treatment of such cancers, including gliomas, such as low-grade gliomas or glioblastomas, which may be recurrent and/or resistant to conventional treatment.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A fusion protein comprises a nanocage monomer or subunit thereof linked to an Fc polypeptide, wherein the Fc polypeptide comprises an IgG4 Fc chain with a mutation at one or more of positions 228, 234, 235, 237, and 238, according to EU numbering, and wherein a plurality of the fusion proteins self-assemble to form a nanocage.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A self-assembled polypeptide complex comprises: (a) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to an Fc polypeptide, and (b) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to a SARS-CoV-2 binding moiety; wherein a plurality of the fusion proteins self-assemble to form a nanocage.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A method of detecting tandem repeat expansions associated with a disease is provided. The method includes the steps of: detecting tandem repeat sequences comprising a repeated motif sequence in nucleic acid samples from individuals within a population of interest, simulating the length distribution of the tandem repeat sequences in the population of interest to a normal distribution if no tandem repeat sequences are detected, and detecting one or more outlier tandem repeat sequences in the tandem repeat sequences detected, wherein an outlier tandem repeat sequence has a length that is greater than that in 90% of the tandem repeat sequences detected in the population interest and occur at a frequency of less than 1% of the tandem repeat sequences detected in a control population. The method is useful for the diagnosis of disease and subsequent treatment of a diagnosed individual.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
49.
OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
Inventor
Julien, Jean-Philippe
Rujas Diez, Edurne
Treanor, Bebhinn
Zhao, Tian Tian
Abstract
In aspects, a self-assembled polypeptide complex comprises (a) a plurality of first fusion polypeptides, each first fusion polypeptide comprising (1) an Fc polypeptide linked to (2) a nanocage monomer or subunit thereof, wherein the Fc polypeptide comprises a Fc chain having one or more mutations relative to a reference Fc chain of the same Ig class, and (b) a plurality of second fusion polypeptides, each second fusion polypeptide comprising (1) an antigen-binding antibody fragment linked to (2) a nanocage monomer or subunit thereof.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
50.
Methods and compositions for screening and treating developmental disorders
This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
51.
METHODS AND COMPOSITIONS FOR INTERFERING WITH FAN1
This disclosure describes methods of altering a FAN1 polypeptide using, without limitation, a polypeptide, an antibody, a nucleic acid, a small molecule, a kinase inhibitor, an agonist of a kinase, an agonist of an exonuclease, or an antagonist of an exonuclease.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage comprising one or more Fc dimers. In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer or scFc fragment at the C-terminus of the nanocage monomer or subunit thereof, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A method of identifying a gene or genomic mutation that is linked to causality of a neuropsychiatric disorder is provided. The method comprises identifying exons which exhibit an expression level that is at least within the 75th percentile of exon expression levels within a nucleic acid-containing sample from a mammal having a neuropsychiatric disorder; comparing the sequence of each identified exon to the sequence of a corresponding exon from a healthy control to identify rare or de novo sequence mutations within the identified exon; calculating the burden of rare or de novo mutations within the exon; and determining the correlation between expression level of the identified exon and burden of de novo or rare mutations in the exon, wherein an inverse correlation indicates that the exon gene is linked to causality of the neuropsychiatric disorder.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 20/40 - Population geneticsLinkage disequilibrium
The Royal Institution for the Advancement of Leaming/McGill University (Canada)
Inventor
Rak, Janusz
Al-Nedawi, Khalid
Meehan, Brian
Guha, Abhijit
Abstract
The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anticancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.
A fusion protein comprises a nanocage monomer or a subunit thereof linked to a DR4 and/or DR5 antigen-binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also described is a nanocage comprising the fusion protein and related compositions as well as methods and uses for treating and/or preventing cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A method of differentiating pluripotent stem cells into hemangioblasts comprising incubating the pluripotent stem cells in a first serum-free differentiation medium comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to induce differentiation of the pluripotent stem cells into hemangioblasts or hemangioblast-containing embryoid bodies is provided. The hemangioblasts or embryoid bodies may be cultured in a second differentiation medium comprising at least granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin-3 (IL-3) for a period of time sufficient to generate alveolar-like macrophages.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
Described herein is an anti-class II MHC antibody fused to a SARS-CoV-2 antigen. Also described is a vaccine comprising the antibody and methods for treating and/or preventing SARS-CoV-2, wherein the methods comprise administering the antibody to a subject in need thereof. In typical aspects, the vaccine is free of an adjuvant.
The present invention relates a system and method for cancer-cell specific transcription identification. The method including: receiving nucleic acid data from one or more samples; determining variant allele fraction (VAF) of markers in ribonucleic acid (RNA) in the nucleic acid data and markers for deoxyribonucleic acid (DNA) in the nucleic acid data; comparing the VAF of the RNA relative to the DNA for each of the markers; and outputting the comparison as a quantification of cancer-cell specific changes in transcriptional output as a marker of prognosis or therapeutic response in cancer.
The disclosure features in some aspects methods for identifying subjects with constitutional mismatch repair deficiency (CMMRD), a mismatch repair deficiency (MMD) cancer, a polymerase proofreading deficiency (PPD) cancer, and/or a MMD&PPD cancer. The disclosure also features in some aspects methods for predicting response of a subject to immunotherapy.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
61.
POLYPEPTIDES TARGETING SARS-COV-2 AND RELATED COMPOSITIONS AND METHODS
Provided herein is a fusion protein comprises a nanocage monomer linked to a SARS-CoV-2 binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also provided is a tri-specific antibody construct targeting SARS-CoV-2. Also provided is a fusion polypeptide comprising (1) a fragment crystallizable (Fc) region linked to (2) a nanocage monomer or subunit thereof, wherein the Fc region comprises the I253A mutation, wherein numbering is according to the EU index.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
64.
COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof.
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 11/00 - Drugs for disorders of the respiratory system
Use of an inhibitor of the ErbB2 receptor for treatment: or repair of nerves and/or nerve tissues is provided. The inhibitor includes art antibody, in particular, a monoclonal antibody, Or example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
THE HOSPITAL FOR SICK CHILDREN (Canada)
Inventor
Diller, Eric
Shokrollahi, Peyman
Parkinson, John
Abstract
A magnetically actuated capsule comprising two portions pivotally connected to each other for allowing tetherless reconfiguration of the capsule between a closed configuration and an open configuration inside a body cavity by an external magnet. The capsule can be used for noninvasive sampling of microbiomes and liquid within a body cavity, or to release a cargo within the body cavity. Methods of using and manufacturing the capsule are disclosed.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
67.
GENE EDITING SYSTEM FOR CORRECTING SPLICING DEFECTS
The present disclosure provides genome editing systems, compositions and methods. The genome editing system comprises at least one nuclease that generates blunt-ended DNA breaks in a sequence-specific manner, wherein the genome editing system is configured to form a first and a second blunt-ended double strand break in an intron of a gene, wherein the intron comprises a splice donor site mutation that alters splice site recognition, thereby excising a segment of the intron and simultaneously joining DNA ends flanking the excised segment of the intron to constitute a functional donor splice site.
Described herein are agents that inhibit CBL autoinhibition, agents that activate CBL, SLAP and/or SLAP2 mimetics, and recombinant SLAP and/or SLAP2 or variants and/or fragments thereof that inhibit CBL autoinhibition. Also described are fusion proteins comprising these molecules as well as methods of inhibiting CBL autoinhibition and related uses thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 9/99 - Enzyme inactivation by chemical treatment
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
69.
HIGH-SPEED CRYOEM SPECIMEN PREPARATION USING THROUGH-GRID WICKING
There is provided a system and method for preparation of an aqueous film comprising a specimen for analysis. The method including: providing a grid structure comprising a first surface and a second surface on a side reverse to the first surface, the grid structure defining a plurality of holes extending from the first surface to the second surface; abutting a wicking material to the second surface; providing a liquid sample on the first surface, the liquid sample comprising the specimen, the wicking material causing a portion of the liquid to be drawn through the plurality of holes and absorbed in the wicking material leaving the aqueous film comprising the specimen on the first surface; and removing the wicking material from the grid structure.
G01N 1/42 - Low-temperature sample treatment, e.g. cryofixation
G01N 23/04 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material
The present disclosure provides a surgical shunt assembly tool that provides a more efficacious grip on the catheter tubes and prevent the tip of the catheter from buckling while the catheter is pushed onto the tip of the valve during installation of shunts during CSF shunt surgery. The tool includes standard handles such as used in a shodded mosquito tool having a clamping jaw integrated into the distal end section of the handle. The distal jaw includes two forcep jaw sections each having a proximal end integrally formed with a distal end of a distal end arm section of one of the two handle arms, and a distal end section extending away from the distal end arm section. The distal end sections of the forcep jaw sections are cylindrically shaped such that when the forcep jaw is closed by bringing the two forcep jaw sections together, a cylinder is formed having a diameter substantially equal to a diameter of a catheter tube to be attached to a shunt valve tip. The proximal ends of the forcep jaw sections are oval shaped and have a size such that when the forcep jaw is closed bringing the two forcep jaw sections together, an oval shaped opening is formed having a size smaller than the diameter of the catheter tube such that the catheter tube is squeezed closed to provide a firm grip of the tool of the catheter tube.
Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.
The present disclosure relates to a method for determining a stem cell type (e.g., reactive, constructive or invasive) in a glioblastoma sample from an individual. Chromatin accessibility genetic data is obtained from the glioblastoma sample, wherein the sample comprises at least one glioblastoma stem cell. An accessibility profile is determined for one or more portions of the chromatin accessibility genetic data, the accessibility profile comprising an accessibility factor for one or more genetic regions. The accessibility profile of the one or more portions of the chromatin accessibility genetic data is compared to one or more corresponding reference accessibility profiles, where the one or more corresponding reference accessibility profiles comprises the accessibility factor of corresponding one or more genetic regions. A signal is outputted to assign the stem cell type to the glioblastoma sample in response to determining that the accessibility profile and the corresponding reference accessibility profile matches to within a predetermined threshold.
Methods of treating diseases caused by repeat DNA instability are described herein. The methods described herein can inhibit the further expansion of repeat DNA and, in some instances, reduce the size of the repeat DNA (e.g., reduce the number of repeats).
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
74.
GENOME-WIDE DETECTION OF DNA REPEATS EXPANDED IN DISEASE
A method of detecting tandem repeat expansions associated with a disease is provided. The method includes the steps of: detecting tandem repeat sequences comprising a repeated motif sequence in nucleic acid samples from individuals within a population of interest, simulating the length distribution of the tandem repeat sequences in the population of interest to a normal distribution if no tandem repeat sequences are detected, and detecting one or more outlier tandem repeat sequences in the tandem repeat sequences detected, wherein an outlier tandem repeat sequence has a length that is greater than that in 90% of the tandem repeat sequences detected in the population interest and occur at a frequency of less than 1% of the tandem repeat sequences detected in a control population. The method is useful for the diagnosis of disease and subsequent treatment of a diagnosed individual.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
75.
Soluble bacterial and fungal proteins and methods and uses thereof in inhibiting and dispersing biofilm
The Royal Institution for the Advancement of Learning/McGill University (Canada)
Inventor
Howell, Lynne P.
Baker, Perrin
Alnabelseya, Noor
Bamford, Natalie
Little, Dustin
Sheppard, Donald
Snarr, Brendan
Lee, Mark Jae
Abstract
The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.
A01N 63/30 - Microbial fungiSubstances produced thereby or obtained therefrom
A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (Germany)
Inventor
Julien, Jean-Philippe
Scally, Stephen
Prieto, Katherine
Wardmann, Hedda
Ludwig, Julia
Murugan, Rajagopal
Costa, Giulia
Levashina, Elena
Abstract
aaaabbbbccccddddeeeee. wherein a, b, c, d, and e are each independently 0 or greater and wherein a+b+c+d+e is at least 2; and a nanocage monomer peptide.
Faecalibacterium, Lachnospira, Coprococcus, Oscillospira. Roseburia, Blautia. Dorea, Parabacteroides or RuminococcusFaecalibacterium, Lachnospira, Coprococcus, Oscillospira. Roseburia, Blautia. Dorea, Parabacteroides or Ruminococcus for treating an atopic disease and two or more of said genera for the diagnostic method.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Acceptance of monetary charitable contributions; acceptance of monetary charitable contributions to fund medical research; charitable fundraising services; philanthropy consulting services, namely, advising others in connection with conducting charitable fundraising campaigns; Acceptance of monetary charitable contributions to fund patient care; acceptance of monetary charitable contributions to fund education; acceptance of monetary charitable contributions to fund education and learning.; Operation of a charitable foundation, namely, a foundation to support activities related to health, research and education; organization of music concerts for charitable fundraising purposes; charitable fundraising services by means of conducting special fundraising events Educational services, namely, conducting distance learning instruction at the college level; Educational services, namely, conducting distance learning instruction at the university level; conducting seminars in the field of oncology; developing fitness programs, namely, physical fitness consultation; developing international student exchange programs; educational research services; educational services, namely, conducting seminars, lectures, workshops and classes in the field of nutrition; Special event planning for social entertainment purposes; lottery services; online publication of electronic books and periodicals; operation of an educational institution at the university level; organization of conferences and symposia in the field of medical science; arranging of seminars, working groups, research groups, and educational conventions in the field of medicine; physical fitness consulting services; physical fitness instruction; publication of electronic books and periodicals online; publishing and issuing scientific papers in relation to medical technology; publishing of journals, books and handbooks in the field of medicine; lottery services; developing international educational programs in the field of medicine; developing international educational programs in the field of medical research; education services namely, providing classes, seminars, workshops and lectures in the field of human reproduction, namely, contraception (particularly, surgical contraception), pregnancy testing, diagnosis and treatment of sexually transmitted diseases namely, AIDS, pregnancy-related education and counseling; Education services, namely, providing educational programs addressing health promotion and disease prevention Bacteriological consultation, research and testing; bacteriological research and testing; basic and clinical research in the field of respiratory science and medicine; biomedical research services; blood analysis services; Conducting clinical trials for others; computer programming in the medical field; conducting early evaluations in the field of new pharmaceuticals; consultancy pertaining to pharmacology; consultation and research in the field of bacteriology; design and testing of new products for others; development of pharmaceutical preparations and medicines; DNA screening for scientific research purposes; electronic storage of medical records; genetic testing for scientific research purposes; laboratory research in the field of bacteriology; material testing services; materials testing and analyzing; medical research; medical research laboratory services; medical research services; pharmaceutical evaluation services; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; product design consulting services; product development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of new products for others; research and development of vaccines and medicines; research and testing in the field of bacteriology; research in the field of biochemistry; research on the subject of pharmaceuticals; scientific research in the field of genetics and genetic engineering; structural and functional analysis of genomes; Basic and clinical research in the fields of obstetrics, neonatal and pediatric care, and lactation; consulting services in the fields of medical research, bacteriological research; product research and development for others; research and development of vaccines and medicines; scientific research in the field of genetics; providing information relating to medical research; providing information in the field of medical research Advisory services relating to weight control; ambulant medical care; behavioral analysis for medical purposes; blood bank services; blood collection services; chiropractic services for children; conducting of medical examinations for insurance purposes; conducting vascular screenings for cardiovascular disease risk factors; consultancy in the field of nutrition; consultancy relating to hearing tests; consultation services relating to skin care; cord blood bank services; counselling relating to occupational therapy; dental clinics; dental consultations; dentist services; dermatological services; diabetes screening services; DNA screening for medical purposes; drug addiction counselling services; drug rehabilitation counselling services; drug screening for medical purposes; drugstore dispensary services in the nature of dispensing of pharmaceuticals; emergency medical assistance; fertility medical clinics; fitting of orthopedic devices; food and nutrition consultation services; genetic counselling; genetic testing for medical purposes; health care consultancy in the field of occupational therapy; health care services for treating cancer; health screening services in the field of asthma; health screening services in the field of sleep apnea; hearing aid fitting services; hearing aid services; home health care services; hospital services; lactation consulting services; leasing of medical equipment; managed health care services, namely, electronic processing of health care information; medical analysis services for cancer diagnosis and prognosis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services for the diagnosis of cancer; surgery for diagnostic purposes; medical care and analysis services relating to patient treatment; medical clinic services; medical clinics; medical consultancy for selecting appropriate wheelchairs, commodes, invalid hoists, walking frames and beds; medical consultancy relating to hearing loss; medical counselling relating to stress; medical diagnostic testing, monitoring and reporting services; medical equipment rental; medical evaluation services for patients receiving rehabilitation for purposes of guiding treatment and assessing effectiveness; medical examination services; medical testing for fitness evaluation; medical house call services; medical imaging; medical imaging services; medical laboratory services for the analysis of blood samples taken from patients; medical nursing services; medical screening; medical screening relating to the heart; medical screening services in the field of asthma; medical screening services in the field of sleep apnea; medical screening services relating to cardiovascular disease; medical services for the treatment of skin cancer; medical services in the field of diabetes; medical services in the field of oncology; medical services in the field of radiology and nuclear medicine; medical services in the field of treatment of chronic pain; medical testing for diagnostic or treatment purposes; medical testing for fitness evaluation; medical testing for diagnostic or treatment purposes; medical testing services relating to the diagnosis and treatment of disease; medical treatment services of circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, oncologic, auto-immune or immune-related, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious, metabolic or central nervous system diseases, illnesses, disorders and conditions provided by clinics and hospitals; mental health screening services; mental health services; mobile dental care services; mobile medical clinic services; nutrition consultancy; nutritional and dietetic consultancy; occupational therapy; occupational therapy and rehabilitation services; occupational therapy services; operation of a wellness center providing dental services; operation of a wellness center providing drug counselling; ophthalmology services; orthodontic services; pediatric nursing services; performance measurement evaluations in the field of health; pharmaceutical consultancy services; pharmacy advice, namely, pharmaceutical advice; pharmacy dispensary services in the nature of dispensing of pharmaceuticals; pharmacy services, namely, preparation of prescriptions in pharmacies; physical therapy; physician services; physiotherapy services; plastic surgery services; preparation and dispensing of medications; preparation of prescriptions in pharmacies; psychological assessment services, namely, preparation of psychological profiles for medical purposes; professional consultancy in the field of medical technology, namely, technology research in the field of medical instruments and apparatus, surgical instruments and apparatus and orthopedic devices; providing breastfeeding information; providing emergency health information by telephone; providing information in the field of orthodontics; providing information relating to the preparation and dispensing of medications; providing information to patients in the field of administering medications; providing information via the Internet in the field of diabetes; providing laser therapy for treating medical conditions; providing medical advice in the field of dermatology; providing medical information in the field of dermatology; provision of information in the field of diabetes via the Internet; psychiatric consultation; psychiatric consulting services; psychological consultation; psychological consultations; psychotherapy and occupational therapy services; public health counselling; rental of beds specially made for medical treatment purposes; rental of medical equipment; rental of medical x-ray apparatus; rental of ultrasonic diagnostic apparatus; rental of ultrasonic medical diagnostic apparatus; respiratory therapy services; sleep disorder medical clinics; speech and hearing therapy services; speech therapy services; standardized psychological testing; healthcare services, namely, treatment of sleep apnea disorders; voice and speech therapy services; X-ray examinations for medical purposes; orthopedic health care services; cardiology health care services; respirology health care services; gastroenterology health care services; endocrinology health care services; hematology health care services; medical services in the field of psychology, psychiatry, dietetics, nutritional counseling, audiology, developmental pediatrics, sleep disorders, diabetes management, pain management, genetic testing, genetic screening, genetic counseling, concussion management, sports medicine, podiatry, orthotics and prosthetics; breastfeeding health clinics; healthcare services in the field of human reproduction, namely, contraception, particularly, surgical contraception, pregnancy testing, diagnosis and treatment of sexually transmitted diseases namely, AIDS, pregnancy-related education and counseling; providing medical information and educational programs addressing health promotion and disease prevention; providing medical information in the fields of obstetrics, neonatal and pediatric care, and lactation; providing medical information addressing health promotion and disease prevention; providing information in the field of medicine; consulting services provided to other healthcare providers and practitioners, in the fields of medical clinic services, medical care relating to patient treatment, ambulant medical care, hospital services, medical examination services and medical diagnostic services; Providing patient advocate services to hospital patients; providing information relating to healthcare; professional consultancy in the field of medical technology, medical surgery and orthopedics
79.
MULTI-VALENT AND MULTI-SPECIFIC NANOPARTICLE PLATFORMS AND METHODS
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
Inventor
Julien, Jean-Philippe
Rujas Diez, Edurne
Treanor, Bebhinn
Zhao, Tiantian
Abstract
A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The Governing Council of the University of Toronto (Canada)
Inventor
Rommens, Johanna M.
Strug, Lisa
Sun, Lei
Abstract
Described herein is a genetic modifier of cystic fibrosis (CF), which may serve as a predictor of the efficacy of a CFTR-directed therapy. SNPs rs7512462 or rs2869027 in non-coding regions of SLC26A9 are shown to correlate with CF lung disease severity in patients having CFTR mutations that leave protein at the cell surface, e.g. gating mutations such as G551D. It is also shown that patient response to Ivacaftor correlates with SLC26A9 genotype. Given the biology of SLC26A9, risk alleles of SLC26A9 should correlate with reduced SLC26A9. SLC26A9 activity (marked by e.g. genotype or expression level) is therefore a predictor of treatment efficacy for any CFTR-directed therapeutic, such as Ivacaftor or Lumacaftor. Associated methods of selecting and treating patients are described, along with related kits, uses, and drug discovery platforms.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
81.
Device for producing continuous negative abdominal pressure
A method of detecting target autoantibodies to actin, connexin-43 and keratin in a mammal is provided. The comprises contacting a biological sample obtained from the mammal with each of actin, connexin-43 and keratin or with antigenic fragments thereof; and detecting the presence of the target autoantibodies in the sample by detecting binding of the target autoantibodies to each of the antigens. The method is useful to diagnose Brugada Syndrome.
There is provided a method of profiling a tumour, the method comprising determining a relative proportion for each of 96 mutation types, wherein the 96 mutation types are defined as the six possible sequence changes C>A, C>G, C>T, T>A, T>C, or T>G in the context of each of four possible nucleotides (A, C, G, or T) at the position immediately 5′ to the mutation and each of four possible nucleotides at the position immediately 3′ to the mutation; assigning the tumour, using the determined relative proportion for each of the 96 mutation types, to at least one of eight clusters defined herein; and determining at least one tumour characteristic based on the assignment to a cluster.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A method of differentiating pluripotent stem cells into hemangioblasts comprising incubating the pluripotent stem cells in a first serum-free differentiation medium comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to induce differentiation of the pluripotent stem cells into hemangioblasts or hemangioblast-containing embryoid bodies is provided. The hemangioblasts or embryoid bodies may be cultured in a second differentiation medium comprising at least granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin-3 (IL-3) for a period of time sufficient to generate alveolar-like macrophages.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
85.
COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof.
This disclosure relates to device for providing continuous negative abdominal pressure (CNAP) which selectively recruits (inflates) the dorsal (spinal region) collapsed areas of the lung, while enabling the patient to remain in the supine (usual) position. The CNAP device includes a rigid frame configured to have a shape and size to envelop a patient's lower chest and abdominal area while in a supine position with the frame having opposed edges which sit on a surface on which the supine patient is resting. A pressure sensor is mounted to the frame for measuring a pressure inside the chamber and is connected to a display for displaying the pressure inside the chamber. An active pressure controller is connected to the pressure sensor, and a vacuum pump is in flow communication with inside the chamber and connected to the active pressure controller. The device includes a top up pump in flow communication with inside the chamber and connected to the active pressure controller which is programmed to instruct the vacuum pump to provide negative pressure in the chamber to start decompressing the chamber, and to instruct the top up pump to maintain the negative pressure in the chamber.
The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
28 - Games; toys; sports equipment
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Audio books; books recorded on disc; computer software for database management; computer software for medical imaging; computer software for organizing and viewing digital images and photographs; computer software for use in cancer diagnosis; contact lenses; corrective eyeglasses; digital books downloadable from the Internet; downloadable digital books; downloadable electronic books; educational software for children; electronic books; electronic glossaries; electronic medical publications; electronic periodicals; eye glasses; eyeglass lenses; laboratory instrument for the detection of pathogens and toxins in a biological sample for research use; pre-recorded audiotapes; pre-recorded digital videodiscs containing topics of instruction in first-aid training; pre-recorded fitness DVDs; pre-recorded optical discs containing information in the field of hospital medical records; pre-recorded videotapes; software for dosimetry purposes in the field of radiotherapy
(2) Books; educational books; manuals; medical identification cards; medical information charts; medical publications; periodical publications; pharmaceutical information leaflets; reference books
(3) Educational games for children; electronic educational game machines designed for children; electronic games for the teaching of children; multiple activity toys for children (1) Development of hospital management systems; hospital administration; medical cost management
(2) Acceptance of monetary charitable contributions; acceptance of monetary charitable contributions to fund medical research; charitable fundraising services;
(3) Conducting distance learning instruction at the college level; conducting distance learning instruction at the university level; conducting seminars in the field of oncology; developing fitness programs; educational research services; educational services in the field of nutrition; online publication of electronic books and periodicals; operation of an educational institution at the university level; organisation of conferences and symposia in the field of medical science; organization of music concerts for charitable purposes; physical fitness consulting services; physical fitness instruction; publication of electronic books and periodicals online; publishing and issuing scientific papers in relation to medical technology; publishing of journals, books and handbooks in the field of medicine; organization of seminars, working groups, research groups and conventions in the field of medicine
(4) Bacteriological consultation, research and testing; bacteriological research and testing; basic and clinical research in the field of respiratory science and medicine; biomedical research services; blood analysis services; clinical trials; computer programming in the medical field; conducting early evaluations in the field of new pharmaceuticals; consultancy pertaining to pharmacology; consultation and research in the field of bacteriology; design and testing of new products for others; development of pharmaceutical preparations and medicines; DNA screening for scientific research purposes; electronic storage of medical records; genetic testing for scientific research purposes; laboratory research in the field of bacteriology; material testing services; materials testing and analysing; medical research; medical research laboratory services; medical research services; pharmaceutical evaluation services; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; product design consulting services; product development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of new products for others; research and development of vaccines and medicines; research and testing in the field of bacteriology; research in the field of biochemistry; research on the subject of pharmaceuticals; scientific research in the field of genetics and genetic engineering; structural and functional analysis of genomes
(5) Advisory services relating to weight control; ambulant medical care; behavioural analysis for medical purposes; blood bank services; blood collection services; chiropractic services for children; conducting of medical examinations; conducting screenings for cardiovascular disease risk factors; consultancy in the field of nutrition; consultancy relating to hearing tests; consultation services relating to skin care; cord blood bank services; counselling relating to occupational therapy; dental clinics; dental consultations; dentist services; dermatological services; diabetes screening services; DNA screening for medical purposes; drug addiction counselling services; drug rehabilitation counselling services; drug screening for medical purposes; drugstore dispensary services; emergency medical assistance; fertility clinics; fitting of orthopedic devices; food and nutrition consultation services; genetic counselling; genetic testing for medical purposes; health care consultancy in the field of occupational therapy; health care services for treating cancer; health screening services in the field of asthma; health screening services in the field of sleep apnea; hearing aid fitting services; hearing aid services; home health care services; lactation consulting services; leasing of medical equipment; medical analysis services for cancer diagnosis and prognosis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services for the diagnosis of cancer; medical and surgical diagnostic services; medical care and analysis services relating to patient treatment; medical clinic services; medical clinics; medical consultancy for selecting appropriate wheelchairs, commodes, invalid hoists, walking frames and beds; medical consultancy relating to hearing loss; medical counselling relating to stress; medical diagnostic services; medical equipment rental; medical evaluation services for patients receiving rehabilitation for purposes of guiding treatment and assessing effectiveness; medical examination services; medical fitness evaluation; medical house call services; medical imaging; medical imaging services; medical laboratory services for the analysis of blood samples taken from patients; medical nursing services; medical screening; medical screening relating to the heart; medical screening services in the field of asthma; medical screening services in the field of sleep apnea; medical screening services relating to cardiovascular disease; medical services for the treatment of skin cancer; medical services in the field of diabetes; medical services in the field of oncology; medical services in the field of radiology and nuclear medicine; medical services in the field of treatment of chronic pain; medical testing for diagnostic or treatment purposes; medical testing for fitness evaluation; medical testing services; medical testing services relating to the diagnosis and treatment of disease; medical treatment services provided by clinics and hospitals; mental health screening services; mental health services; mobile dental care services; mobile medical clinic services; nutrition consultancy; nutritional and dietetic consultancy; occupational therapy; occupational therapy and rehabilitation services; occupational therapy services; operation of a wellness centre providing dental services; operation of a wellness centre providing drug counselling; ophthalmology services; orthodontic services; pediatric nursing services; performance measurement evaluations in the field of health; pharmacy advice; pharmacy dispensary services; pharmacy services; physical therapy; physician services; physiotherapy services; plastic surgery services; preparation and dispensing of medications; preparation of prescriptions in pharmacies; preparation of psychological profiles for medical purposes; professional consultancy in the field of medical technology, medical surgery and orthopaedics; providing breastfeeding information; providing emergency health information by telephone; providing information in the field of orthodontics; providing information relating to the preparation and dispensing of medications; providing information to patients in the field of administering medications; providing information via the Internet in the field of diabetes; providing laser therapy for treating medical conditions; providing medical advice in the field of dermatology; providing medical information in the field of dermatology; provision of information in the field of diabetes via the Internet; psychiatric consultation; psychiatric consulting services; psychological consultation; psychological consultations; psychotherapy and occupational therapy services; public health counselling; rental of beds specially made for medical treatment purposes; rental of medical equipment; rental of medical x-ray apparatus; rental of ultrasonic diagnostic apparatus; rental of ultrasonic medical diagnostic apparatus; respiratory therapy services; sleep disorder clinics; speech and hearing therapy services; speech therapy services; standardized psychological testing; treatment of sleep apnea disorders; voice and speech therapy services; X-ray examinations for medical purposes; pharmaceutical consultancy services, namely pharmaceutical advice and provision of pharmaceutical information
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Electronic formulary; electronic databases in the field of paediatric medicine recorded on computer media; electronic newsletters (1) Operation of a charitable foundation, namely a foundation to support activities related to health, research and education; advocating for access to quality healthcare for children; retail services for pharmaceutical and sanitary preparations and medical supplies; administrative management of health care clinics; cost management in the field of health care
(2) Consulting services, namely advising others in connection with conducting fundraising campaigns; Acceptance of monetary charitable contributions to fund patient care; acceptance of monetary charitable contributions to fund education; acceptance of monetary charitable contributions to fund education and learning
(3) Conducting fundraising events; communicating information relating to healthcare and medical research; developing international educational programs in the field of medicine; developing international educational programs in the field of medical research; sale of lottery tickets
(4) Basic and clinical research in the fields of obstetrics, neonatal and pediatric care, and lactation; international consulting services in the fields of medical research, bacteriological research and testing, research and development of new products for others, research and development of vaccines and medicines, scientific research in the field of genetics
(5) Orthopedic health services; cardiology health services; respirology health services; gastroenterology health services; endocrinology health services; hematology health services; medical services in the field of psychology, psychiatry, dietetics, nutritional counseling, audiology, developmental pediatrics, sleep disorders, diabetes management, pain management, genetic testing, genetic screening, genetic counseling, concussion management, sports medicine, podiatry, orthotics and prosthetics; breastfeeding clinics; healthcare and education services in the field of human reproduction, namely contraception (including surgical contraception), pregnancy testing, diagnosis and treatment of sexually transmitted diseases including AIDS, pregnancy-related education and counseling; providing medical information and educational programs addressing health promotion and disease prevention; providing medical information in the fields of obstetrics, neonatal and pediatric care, and lactation; providing information in the field of medicine and medical research; international consulting services provided to other healthcare providers and practitioners, in the fields of medical clinic services, medical care relating to patient treatment, ambulant medical care, hospital services, medical examination services and medical diagnostic services; managed health care services namely, electronic processing of health care information
(6) Providing patient advocate services to hospital patients
Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Electronic newsletters (1) Operation of a charitable foundation, namely a foundation to support activities related to health, research and education.
(2) Consulting services, namely advising others in connection with conducting fundraising campaigns; acceptance of monetary charitable contributions to fund patient care; acceptance of monetary charitable contributions to fund education; acceptance of monetary charitable contributions to fund education and learning
(3) Conducting fundraising events; communicating information relating to healthcare and medical research; sale of lottery tickets
This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
97.
Nanoparticle platform for antibody and vaccine delivery
The Governing Council of the University of Toronto (Canada)
Inventor
Julien, Jean-Philippe
Sicard, Taylor
Semesi, Anthony
Treanor, Bebhinn
Zhao, Tiantian
Rujas Diez, Edurne
Abstract
A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A capsule shredding device is provided, which includes first and second housing sections. The first housing section has a chamber slightly larger than the capsule located in one end of the housing section so that when the capsule is seated in the chamber it cannot freely rotate in the chamber. A vial is releasably coupled to other end of the first housing section. One or more passageways extend from the bottom of the chamber toward the other end of the second housing section. The second housing section has an internal chamber with a spike extending into the chamber integrally formed on the interior upper section of the housing section. When the two housing sections are threaded together such that are drawn towards each other, the spike pierces the capsule, and upon further rotation the spike shreds the capsule thereby releasing the powder contained therein which flows through the one or more passageways into interior of the vial. Gaskets between the first and second housing sections and between the second housing section and the vial prevent powder or liquid in the vial escaping.
A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
100.
Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.
